Skip to main content
TipRanks
Go Ultimate75% OFF

Matinas BioPharma (6LJ) Stock Price & Analysis

0 Followers

6LJ Stock Chart & Stats

€0.05€0.00(-14.52%)
At close: 5:30 PM GMT+1
€0.1€0.125€0.15€0.175Jun 4Jul 5Aug 21Aug 26
Day’s Range
EUR 0.05 - EUR 0.05
52-Week Range
EUR 0.05 - EUR 0.05
Previous Close
EUR 0.06
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 866.66K
Enterprise Value
EUR 1.94M
Total Cash (Recent Filing)
EUR 761.00K
Total Debt (Recent Filing)
EUR 6,000
Price to Earnings (P/E)
―
Beta
N/A
Next Earnings
N/A
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Minimal debt reduces solvency pressure and limits mandatory interest obligations while the company funds clinical development. This gives Matinas greater financial flexibility than a similarly unprofitable biotech with substantial leverage, although it does not remove the need for external capital.

Improving Losses And Cash Burn

The improvement in losses and cash burn indicates some progress in controlling spending relative to earlier periods. If sustained, this could extend the company’s operating runway and make future financing needs more manageable, even though cash generation remains negative and profitability has not been reached.

LNC Drug Delivery Platform

A platform focused on improving the delivery and tolerability of existing drugs can support multiple product candidates rather than a single therapeutic bet. That creates potential strategic breadth for clinical development, while the company’s clinical-stage status means this platform advantage remains uncommercialized.

Bears Say

No Revenue And Continuing Losses

The absence of meaningful revenue leaves Matinas dependent on financing, partnerships, or successful future commercialization to support operations. Continued sizeable losses also show that the business has not yet demonstrated operating leverage, making durable earnings generation contingent on advancing candidates into revenue-producing products.

Negative Cash Generation And Shrinking Equity

Persistent cash outflows consume the company’s capital base and increase reliance on external funding while clinical programs continue. The sharp decline in equity suggests limited financial resilience and raises the likelihood that future capital needs could materially affect ownership or constrain development if funding is unavailable.

NYSE American Listing Risk

The exchange notice creates a structural financing and market-access risk because continued listing depends on restoring compliance by the remediation deadline. Delisting proceedings could reduce investor access and make future capital raising more difficult, adding pressure to an already thin equity base.

Matinas BioPharma News

6LJ FAQ

What was Matinas BioPharma’s price range in the past 12 months?
Matinas BioPharma lowest stock price was €0.05 and its highest was €0.05 in the past 12 months.
What is Matinas BioPharma’s market cap?
Matinas BioPharma’s market cap is €866.66K.
When is Matinas BioPharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Matinas BioPharma’s earnings last quarter?
Matinas BioPharma released its earnings results on May 07, 2026. The company reported -€0.268 earnings per share for the quarter.
Is Matinas BioPharma overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Matinas BioPharma pay dividends?
Matinas BioPharma does not currently pay dividends.
What is Matinas BioPharma’s EPS estimate?
Matinas BioPharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Matinas BioPharma have?
Matinas BioPharma has 1,113,528 shares outstanding.
What happened to Matinas BioPharma’s price movement after its last earnings report?
Matinas BioPharma reported an EPS of -€0.268 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Matinas BioPharma?
Hedge funds hold Matinas BioPharma shares: the largest hedge-fund position in Matinas BioPharma is 1,579,892,887 shares, and hedge funds decreased their holdings by 129.0K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology